Rabeprazole.
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D015746:Abdominal Pain / Q000139:chemically induced; D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D004381:Duodenal Ulcer / Q000188:drug therapy; D005252:Fees, Pharmaceutical; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D006261:Headache / Q000139:chemically induced; D006801:Humans; D009853:Omeprazole / Q000031:analogs & derivatives; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors; D064750:Rabeprazole
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D064750:Rabeprazole; D000251:Adenosine Triphosphatases; D006180:Proton-Translocating ATPases; D009853:Omeprazole